Apply for Xifaxan (rifaximin)  Copay Assistance & Patient Savings | QuickRx

Xifaxan copay assistance refers to financial support programs — such as manufacturer copay cards, patient assistance programs, and nonprofit foundation grants — that help reduce the out-of-pocket cost of Xifaxan (rifaximin) for eligible patients. QuickRx Specialty Pharmacy provides free enrollment support to help you identify and apply for programs you may qualify for based on your insurance and financial situation. Our patient navigators handle all paperwork so you can focus on your treatment.

Eligibility for Xifaxan copay assistance varies by program. Manufacturer copay card programs are generally available to patients with commercial (private) insurance. Patient assistance programs are typically available to patients who are uninsured, underinsured, or whose government insurance (such as Medicare or Medicaid) does not cover the copay card benefit.

QuickRx evaluates your specific insurance situation to identify the programs you are most likely to qualify for — at no cost to you. Call (917) 830-2525 to speak with a patient navigator.

No. QuickRx Specialty Pharmacy provides copay assistance enrollment support as a completely free service. There are no fees, no hidden charges, and no obligation. Our patient navigator team assists with your Xifaxan application because we believe cost should never be a barrier to managing IBS-D, hepatic encephalopathy, or other conditions treated with rifaximin.

What QuickRx Does For Free:

• Reviews your insurance coverage and identifies all available programs
• Completes copay card and patient assistance applications on your behalf
• Coordinates with your healthcare provider for required documentation
• Manages ongoing renewals and insurance changes
• Researches GI and liver disease foundation grants when additional support is needed
• Provides continuous support throughout your Xifaxan treatment

No. As of the date of this page, there is no FDA-approved generic version of Xifaxan (rifaximin) available in the United States. Xifaxan is currently only available as a brand-name medication. Because no generic alternative exists, manufacturer copay assistance programs and patient assistance programs are especially important for patients who need help affording their rifaximin prescription.

QuickRx patient navigators can help identify every available savings option for brand-name Xifaxan based on your coverage. Call (917) 830-2525 for a free benefits review.

Medicare patients cannot use manufacturer copay cards due to federal regulations. However, other financial assistance options may still be available for Xifaxan.

Options for Medicare Patients:

• Patient assistance programs: May provide Xifaxan at reduced or no cost for qualifying patients based on financial need
• GI and liver disease foundation grants: Nonprofit organizations focused on IBS, liver disease, and gastrointestinal conditions may offer financial assistance regardless of insurance type
• Medicare Extra Help / Low-Income Subsidy: May help with specialty drug costs for qualifying patients
• State pharmaceutical assistance programs: Availability varies by state

QuickRx patient navigators can review your specific Medicare coverage and identify all available options at no cost to you. Call (917) 830-2525 to get started.

Xifaxan (rifaximin) is an oral, minimally absorbed antibiotic approved by the FDA for three indications in adults:

FDA-Approved Indications for Xifaxan:

• Hepatic encephalopathy, prevention of recurrence: Xifaxan is indicated to reduce the risk of hepatic encephalopathy recurrence — a condition involving impaired brain function due to advanced liver disease — in adults.
• Irritable bowel syndrome with diarrhea (IBS-D): Xifaxan is indicated for the treatment of IBS-D in adults. It works locally in the gut with minimal systemic absorption, targeting bacterial factors thought to contribute to IBS-D symptoms.
• Travelers’ diarrhea: Xifaxan is indicated for the treatment of travelers’ diarrhea caused by noninvasive strains of Escherichia coli in adults and pediatric patients 12 years of age and older.

Xifaxan should not be used in patients with diarrhea complicated by fever, blood in the stool, or diarrhea caused by pathogens other than E. coli.

Xifaxan (rifaximin) can be taken with or without food. The dose and duration depend on the condition being treated.

Xifaxan Dosing by Indication:

• Hepatic encephalopathy (prevention of recurrence): 550 mg twice daily
• IBS-D: 550 mg three times daily for 14 days. For patients who experience a recurrence of symptoms, retreatment with the same regimen may be repeated up to two additional times.
• Travelers’ diarrhea (treatment): 200 mg three times daily for 3 days

Important Notes:

• Xifaxan is available as 200 mg and 550 mg tablets — make sure your prescription matches the correct strength for your indication
• If you miss a dose, take it as soon as you remember unless it is almost time for your next dose — do not double up
• Patients with severe liver impairment (Child-Pugh class C) may have increased systemic exposure to rifaximin; use with caution

Always follow your healthcare provider’s specific dosing instructions.

The frequency of side effects with Xifaxan can vary by indication. Side effects are generally reported more frequently in patients using Xifaxan for hepatic encephalopathy than for IBS-D or travelers’ diarrhea.

Common Xifaxan Side Effects (>10%, hepatic encephalopathy use):

• Peripheral edema (swelling in the arms or legs) — 15%
• Nausea — 14% (3% in IBS-D patients)
• Ascites (fluid buildup in the abdomen) — 11%
• Dizziness — 13%
• Fatigue — 12%

Additional Side Effects (1% to 10%):

• Muscle spasm (9%), itching (9%), abdominal pain (9%)
• Anemia (8%), depression (7%), nasopharyngitis (7%)
• Shortness of breath (6%), fever (6%), joint pain (6%)
• Headache (10% in travelers’ diarrhea patients)

Talk to your healthcare provider about any side effects that concern you or that do not go away.

Yes. Xifaxan carries important warnings that patients should discuss with their prescriber.

Important Xifaxan Warnings:

• Ineffective against invasive pathogens: Xifaxan works only in the gut and does not treat systemic infections or diarrhea caused by tissue-invasive bacteria such as Campylobacter, Shigella, or Salmonella. If diarrhea is accompanied by fever or blood in the stool, contact your healthcare provider promptly — Xifaxan is not appropriate and alternative therapy is needed.
• Clostridioides difficile-associated diarrhea (CDAD): As with any antibiotic, C. difficile infection has been reported in patients taking Xifaxan. Contact your doctor immediately if you develop severe, persistent, or bloody diarrhea during or after treatment.
• Severe skin reactions: Rare but serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported with Xifaxan. Seek emergency care immediately if you develop blistering, peeling, or severe rash.
• Hypersensitivity reactions: Serious allergic reactions including anaphylaxis and angioedema have been reported. Seek emergency medical care if you experience difficulty breathing, swelling of the face or throat, or hives.
• Hepatic impairment: The effectiveness of Xifaxan for preventing hepatic encephalopathy has not been established in patients with a MELD score greater than 25. Patients with severe liver impairment (Child-Pugh C) should use Xifaxan with caution due to increased systemic drug exposure.

This information is for educational purposes only. Patients should review all risks with their prescribing healthcare provider before starting Xifaxan.

Xifaxan tablets should be stored properly to maintain medication integrity.

Xifaxan Storage Instructions:

• Store at room temperature between 68°F and 77°F (20°C to 25°C)
• Brief excursions between 59°F and 86°F (15°C to 30°C) are permitted
• Keep in the original container
• Keep out of reach of children

If you have questions about storing your Xifaxan, contact your QuickRx pharmacist at (917) 830-2525.

Irritable bowel syndrome with diarrhea (IBS-D) is a chronic functional gastrointestinal disorder characterized by recurring abdominal pain, discomfort, bloating, and frequent loose or watery stools. Unlike inflammatory bowel disease (IBD), IBS-D does not cause visible damage to the intestines, but it can significantly impact quality of life and daily functioning.

Key Facts About IBS-D:

• IBS-D is one of the most common gastrointestinal conditions, affecting millions of adults in the United States
• The exact cause is not fully understood but may involve gut-brain interactions, altered gut motility, intestinal bacteria, and heightened bowel sensitivity
• Common symptoms include abdominal cramping, urgency, frequent diarrhea, and bloating — often triggered or worsened by certain foods or stress
• Xifaxan (rifaximin) is an FDA-approved treatment for IBS-D in adults and works locally in the gut with minimal absorption into the bloodstream

Patients with IBS-D should work with their gastroenterologist to develop an individualized treatment plan.

Hepatic encephalopathy is a decline in brain function that occurs when the liver is unable to adequately remove toxins — particularly ammonia — from the blood. In patients with advanced liver disease or cirrhosis, these toxins can accumulate and affect brain function, leading to a range of neurological and psychiatric symptoms.

Key Facts About Hepatic Encephalopathy:

• Symptoms can range from mild confusion, forgetfulness, and mood changes to severe disorientation and loss of consciousness
• It most commonly occurs in patients with cirrhosis or advanced chronic liver disease
• Certain triggers — including infections, dehydration, GI bleeding, and constipation — can bring on episodes in patients with underlying liver disease
• Xifaxan (rifaximin) is FDA-approved to reduce the risk of hepatic encephalopathy recurrence in adults, typically used alongside lactulose therapy

Patients with hepatic encephalopathy require ongoing management by a hepatologist or gastroenterologist. If you have been prescribed Xifaxan for this condition, QuickRx patient navigators can help you access copay assistance. Call (917) 830-2525.

Travelers’ diarrhea is a common gastrointestinal illness that occurs when travelers — particularly those visiting developing regions — are exposed to unfamiliar bacteria, most commonly noninvasive strains of Escherichia coli (E. coli). It typically causes sudden onset of loose stools, abdominal cramps, nausea, and occasionally vomiting.

Xifaxan (rifaximin) is FDA-approved for the treatment of travelers’ diarrhea caused by noninvasive E. coli strains in adults and pediatric patients 12 years and older. The standard treatment course is 200 mg three times daily for 3 days.

Important Limitations:

• Xifaxan should NOT be used for travelers’ diarrhea complicated by fever or blood in the stool
• It is not effective against invasive bacterial pathogens such as Campylobacter, Shigella, or Salmonella — these require systemic antibiotics
• If symptoms do not improve within 24 to 48 hours, contact your healthcare provider for alternative treatment

If you have been prescribed Xifaxan for travelers’ diarrhea and need help with costs, call QuickRx at (917) 830-2525.

Yes. Xifaxan (rifaximin) has several clinically important drug interactions. Always inform your healthcare provider and pharmacist of all medications, supplements, and herbal products you are taking.

Notable Xifaxan Drug Interactions:

• P-glycoprotein inhibitors: Medications that inhibit P-gp (including certain HIV protease inhibitors and antifungals) may increase rifaximin blood levels, potentially increasing the risk of side effects — monitor closely
• Warfarin: Rifaximin may reduce the anticoagulant effect of warfarin; blood clotting levels should be monitored during concurrent use
• Cholera vaccine (live, oral) and typhoid vaccine (live, Ty21a): Avoid these live vaccines during and within 14 days of antibiotic therapy, including Xifaxan
• Fecal microbiota (live) products: Concurrent antibiotic use, including Xifaxan, may reduce the effectiveness of live fecal microbiota products — avoid combination
• Mycophenolate: Rifaximin may reduce active drug concentrations of mycophenolate; monitor for reduced immunosuppressive effect
• Immune checkpoint inhibitors: Antibiotics including rifaximin may reduce the effectiveness of anti-PD-1, anti-PD-L1, and anti-CTLA4 cancer therapies — monitor closely

QuickRx pharmacists perform thorough drug interaction reviews as part of the dispensing process. Call (917) 830-2525 with any questions.

Yes. QuickRx Specialty Pharmacy is licensed to dispense and ship Xifaxan (rifaximin) to patients in all 50 states. We provide free home delivery and ensure medications are shipped and handled properly to maintain integrity.

Why Patients Choose QuickRx for Xifaxan:

• Nationwide shipping to all 50 states
• Free copay assistance enrollment services for Xifaxan
• Dedicated patient navigators for IBS-D, hepatic encephalopathy, and GI conditions
• Prior authorization support and appeal assistance
• URAC- and ACHC-accredited specialty pharmacy
• Personal, one-on-one support from enrollment through ongoing treatment

Call us at (917) 830-2525 or complete the form on this page to get started.

QuickRx is a URAC- and ACHC-accredited specialty pharmacy with a dedicated patient navigator team and hands-on financial support services for patients on high-cost specialty medications like Xifaxan.

What Sets QuickRx Apart:

• Dedicated patient navigators specializing in GI conditions, liver disease, and IBS-D
• Free copay card enrollment, patient assistance applications, and foundation grant coordination
• Prior authorization management and appeals support
• Licensed in all 50 states with free home delivery
• URAC- and ACHC-accredited — held to the highest standards in specialty pharmacy
• Personal, continuous support throughout your Xifaxan treatment journey

Our goal is to make sure no patient goes without their Xifaxan due to cost. Complete the form above or call us at (917) 830-2525 to get started today.